MedDataX Logo

Retrospective Analysis for Patients With Metabolic Syndrome

NCT ID: NCT06182618

Last Updated: 2023-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-01

Study Completion Date

2024-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The incidence of metabolic syndrome and related diseases is gradually increasing, and diet and medication are currently common outpatient treatment methods. This study retrospectively analyzes the clinical data of patients with metabolic syndrome and related diseases who have visited our outpatient department in the past 10 years, compares the therapeutic effects of different treatment methods on their blood glucose, blood lipids, blood pressure, uric acid, and body composition, and provides evidence support for clinical treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low-carbohydrate diet

20-30% carbohydrates, 40-45%fat, and 30-40%protein

dietary, semaglutide or/and metformin

Intervention Type OTHER

patients were prescribed dietary and pharmaceuticals for weight loss

balanced diet

50-65% carbohydrate, 20-30% fat and 10-20% protein

dietary, semaglutide or/and metformin

Intervention Type OTHER

patients were prescribed dietary and pharmaceuticals for weight loss

pharmacotherapy

semaglutide (1mg per week) or/and metformin (o.5g three times a day)

dietary, semaglutide or/and metformin

Intervention Type OTHER

patients were prescribed dietary and pharmaceuticals for weight loss

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dietary, semaglutide or/and metformin

patients were prescribed dietary and pharmaceuticals for weight loss

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• individuals who had at least a 2 follow up visits with a BMI of 24 or more with the pri-mary goal of losing weight.

Exclusion Criteria

* patients did not follow-up on a monthly basis;
* patients followed-up less than 1 times within 3 months;
* patients having incomplete data;
* patients changing their interventions during fol-low-ups
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Second Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

leilei wang

Role: CONTACT

Phone: 0571-87783851

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

wang leilei

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-1042

Identifier Type: -

Identifier Source: org_study_id